Neurogene's gene therapy NGN-401 cleared to enter clinic for Rett syndrome

Jan. 24, 2023

Neurogene Inc. has received FDA clearance of its IND application for NGN-401 for the treatment of Rett syndrome. The company plans to initiate a phase I/II trial in female pediatric patients with Rett syndrome this year.

BioWorld Science Neurology/Psychiatric Gene therapy FDA IND

Today's news in brief

BioWorld

BioWorld briefs for March 17, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 17, 2022.

‘Biology no one else will have seen;’ startup Relation seeks new genetic targets

BioWorld

Newco Relation Therapeutics Ltd. is showing its colors after raising $25 million in a seed round to work on integrating single cell transcriptomics, functional...

Nasal spray Zavzpret cleared, Pfizer showing ‘growth on every measure’ in migraine

BioWorld

Pricing won’t be known until later for Pfizer Inc.’s Zavzpret (zavegepant), which became the first and only calcitonin gene-related peptide receptor antagonist...

Affibody in $637M respiratory disease deal with Chiesi

BioWorld

Chiesi Farmaceutici SpA has agreed to pay Affibody AB up to $214 million in a collaboration and licensing agreement to develop an inhaled treatment for...

Upgrade your daily dose of biopharma and medtech news

Neurogene's gene therapy NGN-401 cleared to enter clinic for Rett syndrome